Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, Minnesota 55905


TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow. We will also evaluate whether TG100-115 reduces heart muscle damage.


Inclusion Criteria: - Age 18-80 yrs - ECG patterns consistent with an acute anterior myocardial infarction with ST segment elevation of 2mm in two contiguous ECG leads among leads V1-V4. - Have prolonged, continuous (lasting at least 20 mins) signs and symptoms of myocardial ischemia not eliminated with nitrates. - Intent to proceed to primary PCI within 6 hours of chest pain onset - Sign an informed consent form and be willing to attend follow-up visits for safety and other study assessments. Exclusion Criteria: - Female of childbearing potential. - History of previous myocardial infarction. - History of congestive heart failure. - Requirement for a cardiac pacemaker or defibrillator. - Cardiogenic shock. - Patients previously treated with thrombolytic therapy. - Myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease.



Primary Contact:


Backup Contact:


Location Contact:

Rochester, Minnesota 55905
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.